Stockscreener 앱 받기
24.79
0.60%
-0.15
시간 외 거래:
24.79
전일 마감가:
$24.94
열려 있는:
$24.98
하루 거래량:
576.60K
Relative Volume:
0.22
시가총액:
$307.57M
수익:
$90.12M
순이익/손실:
$-276.06M
주가수익비율:
-16.98
EPS:
-1.46
순현금흐름:
$-193.47M
1주 성능:
+1.56%
1개월 성능:
+191.30%
6개월 성능:
+2,642%
1년 성능:
+1,683%
1일 변동 폭
$24.31
$25.65
1주일 범위
$23.06
$27.72
52주 변동 폭
$0.432
$37.38
넥타테라퓨틱스 Stock (NKTR) Company Profile
명칭
Nektar Therapeutics
전화
(415) 482-5300
주소
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
NKTR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
24.79 | 422.31M | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
넥타테라퓨틱스 Stock (NKTR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-24 | 재확인 | BTIG Research | Buy |
| 2025-06-24 | 재확인 | H.C. Wainwright | Buy |
| 2025-04-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-03-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-01-08 | 개시 | B. Riley Securities | Buy |
| 2024-12-10 | 개시 | H.C. Wainwright | Buy |
| 2024-11-04 | 개시 | Piper Sandler | Overweight |
| 2024-09-30 | 재개 | BTIG Research | Buy |
| 2024-06-28 | 개시 | Rodman & Renshaw | Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-11-09 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | 업그레이드 | Jefferies | Underperform → Hold |
| 2023-02-24 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2022-08-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-31 | 재개 | Jefferies | Hold |
| 2022-04-18 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-03-15 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-08 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-09-10 | 개시 | BofA Securities | Neutral |
| 2021-06-28 | 업그레이드 | Stifel | Hold → Buy |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-02-22 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-09-14 | 개시 | JP Morgan | Neutral |
| 2020-06-10 | 다운그레이드 | CFRA | Hold → Sell |
| 2020-05-12 | 재확인 | H.C. Wainwright | Neutral |
| 2020-04-22 | 개시 | The Benchmark Company | Buy |
| 2020-03-30 | 업그레이드 | Goldman | Sell → Neutral |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-02-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-08 | 다운그레이드 | Goldman | Buy → Sell |
| 2019-08-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-08-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-09 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-03-15 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-06-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | 재확인 | H.C. Wainwright | Buy |
| 2018-04-20 | 개시 | Seaport Global Securities | Buy |
| 2018-04-13 | 재개 | Piper Jaffray | Overweight |
| 2018-04-06 | 재확인 | Mizuho | Buy |
| 2018-04-02 | 재개 | H.C. Wainwright | Buy |
모두보기
넥타테라퓨틱스 주식(NKTR)의 최신 뉴스
Nektar Therapeutics Stock Analysis and ForecastHigh-return market picks - Autocar Professional
Is Nektar Therapeutics a good long term investmentFree Bull & Bear Market Updates - jammulinksnews.com
What drives Nektar Therapeutics stock priceSkyrocketing profit margins - PrintWeekIndia
What analysts say about Nektar Therapeutics stockFree Capital Efficiency Planning - jammulinksnews.com
Nektar Therapeutics Reports Positive Phase 2b Results for Eczema Treatment Rezpegaldesleukin - MSN
Why Nektar Therapeutics Stock Dived by 3% Today - AOL.com
Nektar Therapeutics Announces Pricing of $100 Million Public Offering - 富途牛牛
B-Cell Lymphoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Lisocabtagene maraleucel, Hoffmann-La Roche, Nektar Therapeutics, Miltenyi - Barchart.com
Interleukin-2 Inhibitors Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Yahoo Finance
Rezpegaldesleukin Potentially Promising for Atopic Dermatitis - AJMC
5 Second-Half Biopharma Milestones To Watch - BioSpace
Nektar Therapeutics' experimental eczema drug meets main goal of mid-stage trial - MSN
Nektar Therapeutics Announces Closing of $115 Million Public Off - GuruFocus
Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - WV News
Nektar Raises $115M in Oversubscribed Offering: Major Boost for Immunotherapy Drug Development - Stock Titan
Nektar Therapeutics Prices $100 Million Common Stock Offering - MarketScreener
Nektar Therapeutics launches proposed public offering - MSN
Nektar Therapeutics Announces Public Offering of Shares - TipRanks
Nektar Therapeutics (NKTR) Launches Public Offering - GuruFocus
Nektar Therapeutics (NKTR) Stock Dips Amid $100M Offering - GuruFocus
Nektar Therapeutics Announces Pricing of $100 Million Public Off - GuruFocus
Nektar Therapeutics dips after announcing equity offering - TradingView
Nektar Therapeutics stock falls after announcing public offering By Investing.com - Investing.com Nigeria
Nektar Therapeutics Announces Proposed Public Offering | NKTR Stock News - GuruFocus
Nektar Therapeutics Announces Proposed Public Offering - WV News
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains - TradingView
Nektar Therapeutics stock falls after announcing public offering - Investing.com
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher? - The Globe and Mail
REZOLVE-AD and Rezpegaldesleukin for Atopic Dermatitis, with Jonathan Silverberg, MD, PhD, MPH - HCPLive
Vital Signs: Nektar's Dupixent challenger comes better late than never - FirstWord Pharma
Nektar Nails Phase 2b Eczema Trial: BTIG Calls It A ‘Pound the Table BUY’, Wainwright Sees $120 Upside - MSN
Why Nektar Therapeutics Stock Was Red-Hot Today - MSN
Nektar Therapeutics Leads Stock Market Frenzy With Impressive Gains - Finimize
Nektar Bounces Back As Eczema Drug Rezpeg Heads For Phase III - insights.citeline.com
Nektar (NKTR) Receives Significant Price Target Upgrade | NKTR S - GuruFocus
Why Is Nektar Therapeutics Stock (NKTR) Up 110% Today? - TipRanks
Nektar Therapeutics Soars 156.5% on Positive Atopic Dermatitis Study Results - AInvest
Rezpegaldesleukin: Nektar's Treg Activator Poised to Transform Atopic Dermatitis Treatment - AInvest
Nektar Therapeutics Shares Double On Promising Eczema Drug Data - Benzinga
Nektar Therapeutics stock soars on upcoming atopic dermatitis data By Investing.com - Investing.com South Africa
Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025 - Longview News-Journal
Nektar to announce top-line data from Phase 2b atopic dermatitis trial - Investing.com
Alopecia Areata Market Expected to Experience Major Growth by 2034, According to DelveInsight | Pfizer, Suzhou Zelgen Biopharma, Eli Lilly/ Incyte, Throne Biotech, Legacy Healthcare - Barchart.com
Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC (NKTR) - Seeking Alpha
Nektar Therapeutics (NASDAQ:NKTR) Shares Fly 29% But Investors Aren't Buying For Growth - simplywall.st
넥타테라퓨틱스 (NKTR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):